321 related articles for article (PubMed ID: 19723143)
41. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges.
Grosse-Gehling P; Fargeas CA; Dittfeld C; Garbe Y; Alison MR; Corbeil D; Kunz-Schughart LA
J Pathol; 2013 Feb; 229(3):355-78. PubMed ID: 22899341
[TBL] [Abstract][Full Text] [Related]
42. Immunohistochemical detection of cancer stem cell related markers CD44 and CD133 in metastatic colorectal cancer patients.
Pitule P; Cedikova M; Daum O; Vojtisek J; Vycital O; Hosek P; Treska V; Hes O; Kralickova M; Liska V
Biomed Res Int; 2014; 2014():432139. PubMed ID: 24864242
[TBL] [Abstract][Full Text] [Related]
43. Mutations in the Ras-Raf Axis underlie the prognostic value of CD133 in colorectal cancer.
Kemper K; Versloot M; Cameron K; Colak S; de Sousa e Melo F; de Jong JH; Bleackley J; Vermeulen L; Versteeg R; Koster J; Medema JP
Clin Cancer Res; 2012 Jun; 18(11):3132-41. PubMed ID: 22496204
[TBL] [Abstract][Full Text] [Related]
44. Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas.
Shin JH; Lee YS; Hong YK; Kang CS
J Neurooncol; 2013 Dec; 115(3):333-41. PubMed ID: 24129546
[TBL] [Abstract][Full Text] [Related]
45. Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a meta-analysis.
Ma YC; Yang JY; Yan LN
Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1007-16. PubMed ID: 23478672
[TBL] [Abstract][Full Text] [Related]
46. CD133 mRNA expression and microsatellite instability in colorectal carcinoma.
Huh JW; Park YS; Lee JH; Kim HR; Shin MG; Kim YJ
J Surg Oncol; 2010 Dec; 102(7):765-70. PubMed ID: 20872808
[TBL] [Abstract][Full Text] [Related]
47. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis.
Pallini R; Ricci-Vitiani L; Montano N; Mollinari C; Biffoni M; Cenci T; Pierconti F; Martini M; De Maria R; Larocca LM
Cancer; 2011 Jan; 117(1):162-74. PubMed ID: 20806346
[TBL] [Abstract][Full Text] [Related]
48. Prognostic Value of the Stem Cell Markers Epcam and CD133 Expression Of Gallbladder Adenocarcinoma.
Jiang S; Pei L; Yang ZL; Liu G
Hepatogastroenterology; 2014 May; 61(131):574-9. PubMed ID: 26176038
[TBL] [Abstract][Full Text] [Related]
49. Prognostic value of CD133 expression in stage I lung adenocarcinomas.
Woo T; Okudela K; Mitsui H; Yazawa T; Ogawa N; Tajiri M; Yamamoto T; Rino Y; Kitamura H; Masuda M
Int J Clin Exp Pathol; 2010 Dec; 4(1):32-42. PubMed ID: 21228926
[TBL] [Abstract][Full Text] [Related]
50. Galectin-1 is overexpressed in CD133+ human lung adenocarcinoma cells and promotes their growth and invasiveness.
Zhou X; Li D; Wang X; Zhang B; Zhu H; Zhao J
Oncotarget; 2015 Feb; 6(5):3111-22. PubMed ID: 25605013
[TBL] [Abstract][Full Text] [Related]
51. Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review.
Qu H; Li R; Liu Z; Zhang J; Luo R
Int J Clin Exp Pathol; 2013; 6(11):2644-50. PubMed ID: 24228135
[TBL] [Abstract][Full Text] [Related]
52. DDX4 (DEAD box polypeptide 4) colocalizes with cancer stem cell marker CD133 in ovarian cancers.
Kim KH; Kang YJ; Jo JO; Ock MS; Moon SH; Suh DS; Yoon MS; Park ES; Jeong N; Eo WK; Kim HY; Cha HJ
Biochem Biophys Res Commun; 2014 May; 447(2):315-22. PubMed ID: 24727449
[TBL] [Abstract][Full Text] [Related]
53. Expression patterns of cancer stem cell markers ALDH1 and CD133 correlate with a high risk of malignant transformation of oral leukoplakia.
Liu W; Wu L; Shen XM; Shi LJ; Zhang CP; Xu LQ; Zhou ZT
Int J Cancer; 2013 Feb; 132(4):868-74. PubMed ID: 22782852
[TBL] [Abstract][Full Text] [Related]
54. [Effect of CD133(+) cells on the radiosensitivity of rectal cancer cells].
Qiu J; Yang G; Shen Z; Ding L; Wang D; Wang C
Zhonghua Zhong Liu Za Zhi; 2014 Feb; 36(2):103-8. PubMed ID: 24796457
[TBL] [Abstract][Full Text] [Related]
55. ALDH1 is a prognostic factor for patients treated with neoadjuvant chemoradiotherapy and radical resection for stage III rectal cancer.
Oh SY; Sohn SH; Yim H; Lee D; Suh KW; Kim YB
J Surg Oncol; 2015 Feb; 111(2):243-7. PubMed ID: 25270363
[TBL] [Abstract][Full Text] [Related]
56. Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients.
Artells R; Moreno I; Díaz T; Martínez F; Gel B; Navarro A; Ibeas R; Moreno J; Monzó M
Eur J Cancer; 2010 Feb; 46(3):642-9. PubMed ID: 20005089
[TBL] [Abstract][Full Text] [Related]
57. How powerful is CD133 as a cancer stem cell marker in brain tumors?
Cheng JX; Liu BL; Zhang X
Cancer Treat Rev; 2009 Aug; 35(5):403-8. PubMed ID: 19369008
[TBL] [Abstract][Full Text] [Related]
58. Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status.
Shikina A; Shinto E; Hashiguchi Y; Ueno H; Naito Y; Okamoto K; Kubo T; Fukazawa S; Yamamoto J; Hase K
Jpn J Clin Oncol; 2014 Jan; 44(1):42-8. PubMed ID: 24244031
[TBL] [Abstract][Full Text] [Related]
59. CD133 expression is an independent prognostic marker for low survival in colorectal cancer.
Horst D; Kriegl L; Engel J; Kirchner T; Jung A
Br J Cancer; 2008 Oct; 99(8):1285-9. PubMed ID: 18781171
[TBL] [Abstract][Full Text] [Related]
60. Targeting CD133 antigen in cancer.
Ferrandina G; Petrillo M; Bonanno G; Scambia G
Expert Opin Ther Targets; 2009 Jul; 13(7):823-37. PubMed ID: 19530986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]